Resumen de Investigación

Analyzed using Evidence Intelligence™

Oral Semaglutide Improves Cardiovascular Risk Factors in Diabetes

Desarrollado con el marco Evidence Intelligence™ de Dediabetes

Última actualización 12 de septiembre de 2026

Key finding

HbA1c decreased by 0.87 percentage points

This study evaluated the effects of oral semaglutide on cardiovascular risk factors in patients with type 2 diabetes, showing significant reductions in several metrics.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Follow-up

Long-Term (1–5 y)

Risk of bias

High Risk

Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.

Plain-language summary

What this paper says

A plain-language read of the study’s main message and where it applies.

Study focus

This study evaluated the effects of oral semaglutide on cardiovascular risk factors in patients with type 2 diabetes, showing significant reductions in several metrics.

Clinical relevance

The findings highlight the potential of oral semaglutide as an effective treatment for managing not only blood sugar levels but also cardiovascular risk factors in patients with type 2 diabetes. This could lead to improved overall health outcomes and reduced risk of cardiovascular events in this population.

Keep in mind

Limited sample size may affect generalizability Short duration of the study may not capture long-term effects Some outcomes showed no significant differences

Published in

Referencia de la Revista

Publication details and source links for this paper.

Sharon LM, Silvio EI, Nikolaus M, et al. Oral Semaglutide and Cardiovascular Risk Factors in Patients with Type 2 Diabetes. JAMA Cardiology. 2026;11(5):427-437. doi:10.1001/jamacardio.2026.0245

View DOI View on PubMed View on PMC

Efectos Principales

HbA1c decreased by 0.87 percentage points

Body weight decreased by 2.54%

Systolic blood pressure decreased by 3.84 mm Hg

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Semaglutide and Body weight, C-reactive protein, HDL cholesterol, and 6 more.

This study contributes evidence to

Intervention

Semaglutide

Outcome

Body weight

Evidence topic

Blood Pressure

Primary intervention

Semaglutide

Primary outcomes

Body weight
C-reactive protein
HDL cholesterol

Evidence topics

Blood Pressure HbA1c Reduction Inflammatory and Vascular Markers Weight Loss

Primary intervention

Semaglutide

Primary outcomes

Body weight C-reactive protein HDL cholesterol

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

Evidence pairs

Relationships

Evidence topics

contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 72

Why it is useful

Contributes to 9 evidence relationships
Includes primary outcome data
Linked to 5 direct semantic evidence topics

Topic contributions

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Agrega evidencia relacionada a tu Evidence Tracker

Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.

Evidencia principal

Relación de evidencia

GLP-1 Receptor Agonists and HbA1c

Evidencia relacionada

Relación de evidencia

GLP-1 Receptor Agonists and Body Weight

Guardar evidencia

Relación de evidencia

GLP-1 Receptor Agonists and Adipokine and Angiogenic Markers

Guardar evidencia

Core evidence

Study findings

The primary outcomes reported in this study.

Body weight

Semaglutide → Body weight

Evidence Intelligence™

EvidenceScore™: 86; Strong
ImpactScore™: 76; Positive
ConsistencyScore™: 92; consistent

Basado en 13 estudios

Add to Evidence Tracker

C-reactive protein

Semaglutide → C-reactive protein

Evidence Intelligence™

EvidenceScore™: 78; Strong
ImpactScore™: 67; Slightly Positive
ConsistencyScore™: 67; generally_consistent

Basado en 3 estudios

Add to Evidence Tracker

HbA1c

Semaglutide → HbA1c

Evidence Intelligence™

EvidenceScore™: 88; Strong
ImpactScore™: 87; Very Positive
ConsistencyScore™: 88; consistent

Basado en 16 estudios

Add to Evidence Tracker

HDL cholesterol

Semaglutide → HDL cholesterol

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 100; Very Positive
ConsistencyScore™: unclear; Not enough independent studies

Basado en 1 estudio

Add to Evidence Tracker

Pulse pressure

Semaglutide → Pulse pressure

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 100; Very Positive
ConsistencyScore™: unclear; Not enough independent studies

Basado en 1 estudio

Add to Evidence Tracker

Systolic blood pressure

Semaglutide → Systolic blood pressure

Evidence Intelligence™

EvidenceScore™: 79; Strong
ImpactScore™: 75; Positive
ConsistencyScore™: 75; consistent

Basado en 4 estudios

Add to Evidence Tracker

Total cholesterol

Semaglutide → Total cholesterol

Evidence Intelligence™

EvidenceScore™: Strong; Score 79 · Based on 3 studies
ImpactScore™: 83; Positive
ConsistencyScore™: 100; consistent

Basado en 3 estudios

Add to Evidence Tracker

Triglycerides

Semaglutide → Triglycerides

Evidence Intelligence™

EvidenceScore™: Strong; Score 79 · Based on 3 studies
ImpactScore™: 83; Positive
ConsistencyScore™: 100; consistent

Basado en 3 estudios

Add to Evidence Tracker

Very-low-density lipoprotein cholesterol

Semaglutide → Very-low-density lipoprotein cholesterol

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 100; Very Positive
ConsistencyScore™: unclear; Not enough independent studies

Basado en 1 estudio

Add to Evidence Tracker

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

La Evidencia Sugiere

HbA1c levels decreased by 0.87 percentage points with oral semaglutide
Body weight reduced by 2.54% in participants taking the medication
Systolic blood pressure decreased by 3.84 mm Hg

A quién se aplica

Adults diagnosed with type 2 diabetes
Patients seeking to manage cardiovascular risk factors

Tener en Cuenta

Results may not apply to all demographics or age groups
Further research is needed to confirm long-term effects
The study did not measure all potential confounding factors

Entre Líneas

Limited sample size may affect generalizability
Short duration of the study may not capture long-term effects
Some outcomes showed no significant differences

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

Desarrollado con el marco Evidence Intelligence™ de Dediabetes

This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, GLP-1 Receptor Agonists and Body Weight.

Relaciones de evidencia relacionadas

Explore in Evidence Explorer

This study contributes to the evidence on the following intervention-outcome relationships.

Medications

Detailed evidence

GLP-1 Receptor Agonists → HbA1c

Medications

Evidence Intelligence™

EvidenceScore™: 88; Strong
ImpactScore™: 87; Very Positive
ConsistencyScore™: 88; consistent

Basado en 16 estudios

View evidence

Medications

Detailed evidence

GLP-1 Receptor Agonists → Body Weight

Medications

Evidence Intelligence™

EvidenceScore™: 86; Strong
ImpactScore™: 76; Positive
ConsistencyScore™: 92; consistent

Basado en 13 estudios

View evidence

Medications

Detailed evidence

GLP-1 Receptor Agonists → Adipokine and Angiogenic Markers

Medications

Evidence Intelligence™

EvidenceScore™: Strong; Score 79 · Based on 3 studies
ImpactScore™: 83; Positive
ConsistencyScore™: 100; consistent

Basado en 3 estudios

View evidence

Incluido en estas colecciones de evidencia

Curated evidence collections and hubs this study is part of.

GLP-1 Receptor Agonists Evidence Hub

All studies on GLP-1 Receptor Agonists

16 studies

intervention_hub

Contributes to GLP-1 Receptor Agonists evidence base.

HbA1c Evidence Hub

All studies measuring HbA1c

16 studies

outcome_hub

Measures HbA1c as a key outcome.

Body Weight Evidence Hub

All studies measuring Body Weight

13 studies

outcome_hub

Measures Body Weight as a key outcome.

Adipokine and Angiogenic Markers Evidence Hub

All studies measuring Adipokine and Angiogenic Markers

3 studies

outcome_hub

Measures Adipokine and Angiogenic Markers as a key outcome.

Recent Diabetes Research

Latest published studies

recency_collection

Published within the last 2 years.

Explora más en Evidence Explorer

Jump to pre-filtered views in Evidence Explorer.

All studies on Semaglutide and HbA1c

Intervention: SemaglutideOutcome: HbA1c

16 results

All studies on Semaglutide and Body weight

Intervention: SemaglutideOutcome: Body weight

13 results

All studies on Semaglutide

Intervention: Semaglutide

16 results

All studies measuring HbA1c

Outcome: HbA1c

16 results

All studies measuring Body weight

Outcome: Body weight

13 results

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Do GLP-1 Receptor Agonists lower HbA1c?

Strong Evidence

GLP-1 Receptor Agonists appear to lower HbA1c.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 88.2 | strong positive | ConsistencyScore™ Consistent | 1 study

Why this answer: This answer is based on 45 supporting studies with consistent results and a positive effect signal.

View Full Evidence

Do GLP-1 Receptor Agonists affect body weight?

Strong Evidence

GLP-1 Receptor Agonists may affect body weight.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
Body weight
EvidenceScore™ Strong | EvidenceScore™ 85.8 | moderate positive | ConsistencyScore™ Consistent | 1 study

Why this answer: This answer is based on 43 supporting studies with consistent results and a positive effect signal.

View Full Evidence

Do GLP-1 Receptor Agonists improve adipokine and angiogenic markers?

Strong Evidence

GLP-1 Receptor Agonists may improve adipokine and angiogenic markers.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
Total cholesterol
EvidenceScore™ Strong | EvidenceScore™ 79.0 | moderate positive | ConsistencyScore™ Consistent | 1 study
2
Triglycerides
EvidenceScore™ Strong | EvidenceScore™ 79.0 | moderate positive | ConsistencyScore™ Consistent | 1 study
3
HDL cholesterol
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on 13 supporting studies with consistent results and a positive effect signal.

View Full Evidence

Do GLP-1 Receptor Agonists improve blood pressure?

Strong Evidence

GLP-1 Receptor Agonists may improve blood pressure.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
Systolic blood pressure
EvidenceScore™ Strong | EvidenceScore™ 78.8 | moderate positive | ConsistencyScore™ Consistent | 1 study
2
Pulse pressure
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on 14 supporting studies with consistent results and a positive effect signal.

View Full Evidence

Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

Blood Pressure Evidence Hub HbA1c Reduction Evidence Hub Inflammatory and Vascular Markers Evidence Hub Weight Loss Evidence Hub

Explore in Evidence Explorer

Open broader Evidence Explorer views for this relationship.

All studies on Semaglutide and HbA1c All studies on Semaglutide and Body weight All studies on Semaglutide and Total cholesterol All studies on Semaglutide and Triglycerides

Related research

Read related research summaries.

Video education improves dietary compliance for diabetes Semaglutide may reduce cardiovascular events in non-diabetic patients.Oral semaglutide reduces cardiovascular events in type 2 diabetes Semaglutide improves insulin sensitivity in adolescents with obesity High-protein diet may reduce cardiometabolic risks in diabetes patients

Sin anuncios. Sin rastreo.

Centrada en la evidencia, no en la publicidad.

Segura y privada

Tus datos siempre están protegidos.

Siempre al día

Se agregan nuevos estudios todos los días.